TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Cardiac events prediction
Endpoint domain: Mortality/survival
Primary endpoint: Cardiac death prediction
Endpoint domain: Mortality/survival
Primary endpoint: block extension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain-free status within 2 hours postdose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: chest-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: number of ribs fractured
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of randomized participants
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Risk of cardiovascular death or hospital admission for worsening heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Grades 3-4 neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: Vermont Disability Prediction Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean lowering of calcemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Knee extensors torque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety profile of the drug
Endpoint domain: Adverse events/effects
Primary endpoint: Increase in IIEF scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: thickness of the enamel smear layer
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cataract surgery occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Intraocular pressure elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Glaucoma occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Recognition of anaphylaxis symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of body organ systems involved in severe or fatal anaphylaxis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Balance Score (BS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Reach Test (FRT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: regression to normoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sialic acid concentrations in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sialic acid concentrations in saliva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pink Esthetic Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Digoxin area under the plasma concentration-time curve (AUC) from 0 to 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Digoxin area under the plasma concentration-time curve (AUC) from 0 to 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total score of compressions correct
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compression depth scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hand position score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of clinically defined UTI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Rates of attrition
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvements in cognitive inefficiencies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pericardial effusion (PE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Left ventricular diastolic dysfunction (LVDD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pulmonary artery hypertension (PAH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pro-inflammatory tumor necrosis factor (TNF)-alpha production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: anti-inflammatory IL-1ra and IL-10 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: TPS difference between rupatadine and placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SD of home BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: SD of home HR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: 90-day HRQOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Intraoperative propofol C(e)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of investigator-assessed gynecomastia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Closeness to non-sufferers and fellow sufferers
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Optimism-sociability decline
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bodily discomfort increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FIB content in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: DD content in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Psychopathology symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LESP (Lower Esophageal Sphincter Pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of ineffective esophageal contractions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean enophthalmos
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessed with visual analogue scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days of hospitalisation
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: NVAS pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve ITR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transition to oral antihypertensive therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: true-positive findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of new enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atherogenic indices (CRI-I, CRI-II, AC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of atopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk of wheezing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: postprandial satiety hormone responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Changes in canal space
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Lp-PLA(2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: fine and gross motor skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative incidence of interval-cancer cases
Endpoint domain: Mortality/survival
Primary endpoint: cumulative incidence of T2+/node-positive status breast cancer cases
Endpoint domain: Mortality/survival
Primary endpoint: duration of initial analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for blood transfusions
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of suspected and confirmed sepsis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of suspected and confirmed necrotizing enterocolitis (NEC)
Endpoint domain: Adverse events/effects
Primary endpoint: Residual myopia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speech function scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: between-meal caloric intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in disability as measured by the Roland-Morris Disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Post-occlusion oxygen partial pressure (Post-PaO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-harm incidence
Endpoint domain: Adverse events/effects
Primary endpoint: EPS concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: in situ demineralization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PSTS ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Scale for odynophagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in sexual functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with the PE-program
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Implementation of ergonomic solutions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Transferrin saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Acuity (VA) gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mental health and perception of general health scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Final pain levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival crevicular fluid levels of TIMP-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival crevicular fluid levels of MMP-8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gingival crevicular fluid levels of IL-1β
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gain of >3 lines of Snellen acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of CCSVI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: PDAI improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Marginal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and connective tissue outcomes
Primary endpoint: QALYs loss
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: SHUEE dynamic positional analysis (DPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric Quality of Life Inventory (PedsQL) CP module domain of movement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Canadian Occupational Performance Measure (COPM) score for satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Risk of benign proliferative breast disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Antiviral treatment duration
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Antiviral costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quality adjusted life-year gained
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall time to progression
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in addiction-related symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in trauma symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in functionality
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction of CIED infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: risk of total prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: risk of lower grade prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: risk of higher grade prostate cancer
Endpoint domain: Mortality/survival
Primary endpoint: non-CABG related bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: 30-day net clinical effect (NACE)
Endpoint domain: Mortality/survival
Primary endpoint: Brain's responses to cues associated with alcohol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: number of new Gd + lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mesor of the CRTre
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: amplitude of the CRTre
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Promoting remineralization of enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preventing demineralization of enamel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque metabolism measures for ammonia production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of shoulder tip pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean corneal concentration of levofloxacin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0,t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in state anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Knockdown time (KDT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC) of trans-resveratrol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean maximum plasma trans-resveratrol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RMET performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TASIT performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DAS28CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quality of life improvements (HAQ, SF12PCS, EQ-5D)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Need for further pleural procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: MACE risk reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean decrease in diastolic blood pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of patients with normalized DBP (<90 mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of pathological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Major grade 3 or 4 hematological toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: obesity-related outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMD gains at total hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMD gains at femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BMD gains at lumbar spine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful discharge rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median length of initial hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Renal clearance of 1-MX
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Review quality score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of major errors identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likelihood of recommending rejection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: primary virological response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep duration and efficiency
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: global sleep and well-being
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: tiredness and energy
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Reduction in mean sitting SBP/DBP (msSBP/msDBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: BP control (msSBP/msDBP < 140/90 mmHg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean repigmentation grades
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Allogeneic packed red blood cell transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total creatine kinase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Head circumference at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biparietal diameter at gestational week 32
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length at birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24th hour pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 48th hour pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean re-epithelization time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Responder rate based on diary cards
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serious perinatal complications
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of patient movement
Endpoint domain: Adverse events/effects
Primary endpoint: Number of electrical cardioversions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of pacemaker insertions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: physician-rated healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: self-reported pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Impairment rates on Block Design and Arithmetic subtests
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time to complete response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean increase in mitral valve area (MVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Embolic events during procedure
Endpoint domain: Adverse events/effects
Primary endpoint: mean cumulative response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: role functioning improvement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: locomotor skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall FMS competence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived teacher support
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: TAG AUC variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean MLSI composite stain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fever and injection site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Serum antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody response to pertussis antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PROMIS Fatigue scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Total dose of morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain in motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sphincter-preserving rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative analgesia duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30% PSAD
Endpoint domain: Mortality/survival
Primary endpoint: Measurable disease response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily activity levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Long-term bleeding control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes